nivolumab,ipilimumab
bms
['ipi+', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'nivo', 'niche-2']
 niche-2 trial from la (ct3+/n+) dmmr crc (63%t4) 1x ipi+nivo 1x nivo surgery 61% any grade aes (4%g3+ ; 2% surgery delay) 100% r0 resection (98% timely) 95% major pr ; 67% pcr mfup 13.1m = no recurrences! 3y dfs 2023
#esmo22 
Medical Oncologist at Hospital Sírio-Libanês Translational Oncology ?? Former fellow @FellowsHsl ???? @ASCO Trainee & Early Career Advisory Group